Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

4.750 UNCHANGED
Streaming Delayed Price Updated: 2:42 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7
Open 4.750
Bid (Size) 4.420 (2)
Ask (Size) 6.000 (1)
Prev. Close 4.750
Today's Range 4.750 - 4.750
52wk Range 4.700 - 40.80
Shares Outstanding 52,997,814
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
From Aprea Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
 
Via Benzinga

Performance

YTD
-36.66%
-36.66%
1 Month
-24.60%
-24.60%
3 Month
-33.47%
-33.47%
6 Month
-68.94%
-68.94%
1 Year
-87.30%
-87.30%

More News

Read More
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
From Aprea Therapeutics
Via Globe NewsWire
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Aprea Therapeutics
Via Globe NewsWire
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via Globe NewsWire
Why Aprea Therapeutics Shares Hit A New 52-Week Low Today
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
From Aprea Therapeutics
Via Globe NewsWire
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
From Aprea Therapeutics
Via Globe NewsWire
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
From Aprea Therapeutics
Via Globe NewsWire
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
From Aprea Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
From Aprea Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
From Aprea Therapeutics
Via Globe NewsWire
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via Globe NewsWire
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Via Benzinga
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.